Acknowledgments Funding for this research
was provided by Shire Development LLC to Xcenda and AMF Consulting. Shire is a manufacturer of products that are used for the treatment of ADHD. VS, PH, and MHE are employees of Shire and are stock/option owners of Shire. AB was an employee of Xcenda at the time of this study. MF is an independent statistical consultant with AMF Consulting. Melissa Brunckhorst, from MedErgy, provided editorial assistance in formatting, proofreading, and copy editing. This support was funded by Shire. Gina D’Angelo, PharmD, from Shire also reviewed and edited the manuscript for scientific accuracy. Although the sponsor was involved in the design, collection, analysis, interpretation, and fact checking of information, the content of this manuscript, see more the ultimate interpretation, and the decision to submit it for publication in Drugs in R&D were made by all the authors independently. Conflict of interest VS, PH, and MHE are employees of Shire and hold stock/options in Shire. MF is an independent statistical consultant with AMF Consulting, which received funding from Shire Development LLC for this study. AB was an employee of Xcenda during the time of this study, which received funding from Shire Development LLC for this study. Open AccessThis article is distributed under the terms of the Creative
Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided
the original www.selleckchem.com/products/sotrastaurin-aeb071.html author(s) and the source are credited. References 1. National Institute of Mental Health. Attention deficit hyperactivity disorder (ADHD). 08-3572 ed. US Department of Health and Human Services; 2008. http://www.nimh.nih.gov/health/publications/attention-deficit-hyperactivity-disorder/adhd_booklet_cl508.pdf. 2. National Institute for Health and Poziotinib Clinical Excellence. Attention deficit hyperactivity disorder: the diagnosis and management of ADHD in children, young people and adults. NICE clinical guideline 72. 2008. p. 1–56. http://www.nice.org.uk/nicemedia/pdf/cg72niceguidelinev3.pdf 3. Brod M, Pohlman B, Lasser R, Hodgkins P. Comparison of the burden of illness for adults with ADHD across seven countries: a qualitative find more study. Health Qual Life Outcomes. 2012;10(47). 4. Hodgkins P, Sasane R, Meijer WM. Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands. Clin Ther. 2011;33(2):188–203.PubMedCrossRef 5. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942–8.PubMedCrossRef 6. Atkinson M, Hollis C. NICE guideline: attention deficit hyperactivity disorder.